DSIP
Delta Sleep-Inducing Peptide (Emideltide)
Access and compounding status raise extra safety and legal questions.
A small natural peptide first discovered in 1977 that promotes deep sleep activity in brain wave recordings. Small human studies in people with insomnia showed some positive but modest results. It is not FDA-approved and is not available through regular pharmacies.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Formal safety data are limited. DSIP has been described as 'incredibly safe' in a 2001 editorial, noting that no dose had ever killed an animal subject and no significant side effects apart from transient headache, nausea, and vertigo in humans have been reported. The Schneider-Helmert studies reported no daytime sedation or side effects (PMID 7028502). In the Dick 1984 withdrawal study, tolerance was good aside from headaches in a few patients (PMID 6548969). The FDA has raised concerns about potential immunogenicity risk with certain routes of administration (FDA.gov Category 2 list). Long-term safety data are lacking. A bell-shaped dose-response curve means higher doses may paradoxically reduce effectiveness or cause stimulation (PMID 6145137, PMID 2322843). Community reports of vivid/lucid dreams are common but are anecdotal rather than controlled safety data.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-24]